伊利股份 (600887SS)
布局有利形势 - 买入，并加入强力买入名单（摘要）
我们认为未来即将出现两方面明确的信号推动伊利估值向上重估：1) 公司在过去3
个月里加紧了推广，凭借主要高端产品扩大其市场领先地位。我们预计公司销售额
在经历了五个表现平平的季度后，将从2017 年二季度开始以接近两位数的速度同
比增长； 2) 2017 年下半年里，我们预计国内供应削减以及进口下降将推动原奶价
格进入上行周期。由于竞争相应放缓，我们认为2017 年伊利将能够降低其整体广
告促销开支率，抵消成本压力。因此我们目前预计2016-18 年营业利润和每股盈
利的年均复合增速分别为16%和9%。重申对该股的买入评级，并作为我们在该板
块的首选股而加入强力买入名单，12 个月目标价格为人民币229 元，隐含19%
1) 销售额从2017 年二季度开始加速增长：我们预计2017 年二三季度销售额增速
为9%，而过去五个季度的增速处于-3%。推动销售额加速增长的主要因素在于
常温酸奶高档常温奶进一步强劲增长以及液态奶最近促销力度加大。婴幼儿配方
奶业务也在逐步复苏。2) 控制广告促销开支以及2017 年下半年的原奶价格上行周
期将抵消毛利率压力：我们估测2017 年伊利的广告促销开支率将同比下降50 个
基点。考虑到国内供应削减（因为在当前奶价下，小规模奶农退出无利可图的生
产）以及进口下降（因为全球中国奶价缺口收窄），我们认为2017 年下半年中国
原奶价格将复苏。在我们看来，这将缓解竞争压力并且下游领先企业将收益最大。
3) 收购并购：由于伊利将实现其2020 年人民币1000 亿元的销售目标，我们预计
收购并购将成为对公司未来两年增长愈发重要的来源。我们认为海外高端品牌非
乳业业务可能成为潜在选项，从而令伊利当前的产品结构多元化。
我们将2018-20 年每股盈利预测上调至多3%，并将12 个月目标价格从人民币
2240 元上调至2290 元，基于2018 年预期EVGCI vs CROCIWACC（行业现
金回报倍数仍为09 倍）。我们的目标价格隐含20 倍的2018 年预期市盈率。
液态奶销售放缓，毛利率下降，收购并购带来摊薄影响。
全文翻译将随后提供
存在业务关系，并且继续寻求发展这些关系。因此，投资者应当考虑
到本公司可能存在可能影响本报告客观性的利益冲突，不应视本报告
信息披露附录，或请与您的投资代表联系。
 回报- 资本回报率
报告的信息披露部分。
12个月目标价格(Rmb)
市值(Rmb mn  US mn)
每股盈利(Rmb) 新
每股盈利调整幅度(%)
每股摊薄盈利(Rmb) 新
EVEBITDA(X)
相对于沪深300指数
资料来源：公司数据、高盛研究预测、FactSet（股价为5252017收盘价）
伊利股份 (600887SS)
伊利股份： 财务数据概要
损益表(Rmb mn)
资产负债表(Rmb mn)
销售、一般及管理费用
其它营业收入（支出）
每股基本盈利（非经常性项目前）(Rmb)
每股基本盈利（非经常性项目后）(Rmb)
每股摊薄盈利（非经常性项目后）(Rmb)
每股净资产(Rmb)
自由现金流收益率(%)
增长率和利润率(%)
平均运用资本回报率(%)
净负债股东权益(%)
EBIT利息保障倍数(X)
现金流量表(Rmb mn)
EVEBITDA(X)
企业价值总投资现金(X)
支付股息的现金（普通股和优先股）
注：最后一个实际年度数据可能包括已公布和预测数据。
资料来源：公司数据、高盛研究预测
伊利股份 (600887SS)
Faster sales from 2Q17 further market share gains
Following five quarters of slowerflattish sales growth we now expect acceleration to a high
single-digit yoy rate from 2Q17 and sustained growth of 7-8% over the next two years
Continued liquid milk market share gains from best-selling products increased promotional
intensity and gradual recovery of the infant milk formula (IMF) market will be the main drivers of
faster growth in our view
Exhibit 1 Yili sales to accelerate to a high-single-digit
yoy rate from 2Q17
Exhibit 2 Extending dominance in liquid milk share
Yilis China market share
Source Company data Goldman Sachs Global Investment Research
Source Nielsen
Increasing promotional activity to drive sales
We have seen in the past few months that Yili has started to increase promotional intensity
especially in key product SKUs such as Satine its premium UHT long-life product
The data we track from Carrefour supermarket in Shanghai indicate Yili has offered on average
17% price discounts for Satine vs almost no price discount for Mengnius Milk Deluxe in 1Q17
The discount for Satine is larger than in 2H16 (-5% on average) but similar to 1H16s level We
focus more on sales growth and target an 8% increase in organic sales for 2017 We expect Yilis
sales to start benefiting from this strategic move from 2Q17 and we see both leaders Yili and
Mengniu gaining market share from the small regional players
Room Temp
Market share (%)
伊利股份 (600887SS)
Exhibit 3 Yili recently added price discounts for premium
UHT milk to stimulate sales
Price discounts  Premium UHT
intense in 2017
Price discounts  UHT yogurt
Source Carrefour Shanghai
Source Carrefour Shanghai
Premium UHT milk and yogurt are key growth drivers
As illustrated in Exhibits 5 and 6 we expect UHTchilled yogurt and premium UHT milk to
contribute the most to Yilis topline driving the acceleration for 2017
We see the UHT yogurt market continuing to grow at a high-teens yoy rate in 2017 and look for
Yili to extend its leadership with a 45% market share (vs less than 30% in 2015) We forecast that
Yilis Ambrosial drinkable yoghurt product will record Rmb10bn sales in 2017 (40% yoy) driven
by active marketing campaigns and more product packagetaste SKUs
Exhibit 5 We see UHT and chilled yogurt to contribute
the most increase to topline for 2017
Yili sales growth breakdown  2017
Exhibit 6 Yili Satine UHT yogurt sales to reach
Rmb10bn7bn level in 2017
Source Company data Goldman Sachs Global Investment Research
Source Company data Goldman Sachs Global Investment Research
New products Yili has recently launched a new bottle-shaped package for Ambrosial Also
Rmb92110g These products cater increasingly to urban consumers who are willing to pay extra
for healthy and tasty products New products contributed about 20% of sales in 2016 and Yili is
targeting another 15-20% contribution from new products again in 2017
Discount from original price
Premium UHT Milk Discount from Original price
Discount from original price
UHT Yoghurt Discount from Original price
Yili Ambrosial
Bright Momchilovtsi
Mengniu Just Yogurt
2016 Sales
2017 Sales
伊利股份 (600887SS)
Exhibit 7 Bottle type Ambrosial launched in May
Exhibit 8 following the launch of a new premium
product Pureday earlier in 2017
Chilled yogurt product
Source Company data
Source Company data
IMF gradual recovery in 2H17 expect 8% Yili IMF growth
IMF industry sales turned downward yoy in 2016 on a 3% drop in ASP vs a 2% rise in volume
but Nielsen data indicate a gradual recovery in 1Q17 with 5% growth from ASP and 2% from
volume With a more favorable demographic trend in 2017 (2016 newborns grew over 10% yoy)
we expect stronger demand for stage 1-2 products in 2017 Further we believe stringent
consumers and their formulas are also less likely to register  successfully)
for 1H17 However with smaller brands continuing to exit the market and with the first batch of
registered brands (those for which formulas are registered with the China regulatory authorities)
inventory in 2H17
The latest Nielsen data show that Yili maintains a stable market share in offline channels (Exhibit
10) and we expect 8% IMF sales growth in 2017 vs a 15% decline in 2016
Exhibit 9 IMF industry sales recovered in 1Q17
IMF industry volume ASP yoy
Exhibit 10 Yili has maintained a steady share of 5-6%
Nielsen market share data for IMF
Source Company data Nielsen Euromonitor
Source Nielsen
MEAD JOHNSON
Wyeth 158%
BEINGMATE 45%
DANONE 100%
YILI CORP 57%
BIOSTIME 67%
ABBOTT 83%
YILI CORP
伊利股份 (600887SS)
Product mix lower AP ratio to offset gross margin pressure
We believe the market may have concerns about margin pressure on Yili in 2017 In 1Q17 Yilis
GPM dropped by 400bps yoy due to rising packaging material costs while recently added price
promotions could also negatively impact GPM for the rest of year
However we believe a better product mix and declining AP ratio should largely offset
the cost pressure
1) We expect steady 4-5% ASP growth from product mix over 2017-2018E (62% in 2016)
on stronger growth in flagship products
2) We believe Yili will start to lower its AP expenses ratio in 2017 in contrast to the sharp
increase over the past three years In 1Q Yili recorded 400bps yoy lower selling expenses and we
and expects a flattish ratio in 2017
3) Cost pressures more contained The main rising cost for Yili is paper products which
stay at a flat level yoy for 2017 as a whole in our view In 1H17 we see a continued yoy decline in
raw milk cost while we expect a gradual increase starting from 2H17
Hence we expect Yilis gross margin minus selling expenses (ie OPM) to remain stable for full-
year 2017
Exhibit 11 1Q17 GPM was impacted by rising cost and
promotions
Exhibit 12 but we see still stable OPM due to lower
SGA as % of sales
Source Company data Goldman Sachs Global Investment Research
Source Company data Goldman Sachs Global Investment Research
伊利股份 (600887SS)
Exhibit 13 Paper and sugar cost rises faster in 2017
Yili liquid milk COGS breakdown
Exhibit 14 yet Yili further improves product mix
partially offsetting the higher cost
Yili per liter profit breakdown
Source Company data Goldman Sachs Global Investment Research
Source Company data Goldman Sachs Global Investment Research
Exhibit 15 Yilis AP level should taper on better
supplydemand balance
Exhibit 16 and thus we see a stable OPM trend in 2017-
Gross profits after selling expenses vs milk cost
Source Company data Goldman Sachs Global Investment Research
Source Company data Goldman Sachs Global Investment Research
Improved balance of milk supplydemand in 2H17 likely to drive milk price uptrend and
China milk production has continued to shrink since early 2016 The latest Mar-Apr 2017 data
indicate milk supply fell back into negative territory after 1Q16s increase (Exhibit 17) The decline
has been driven by smaller farmers exiting production due to current milk prices not making profit
Although the China raw milk price has remained at a weak level over the past 3 months we
highlight that the gap between China and global milk prices has more or less disappeared (China
landed cost basis) and hence we expect a continued decline in milk powder imports for the rest of
We now expect the China raw milk price to bottom out and recover gradually in 2H17 This should
We believe that industry leaders will benefit most from a recovery in the supplydemand
balance given that an increase in cost will reduce the incentive of smaller players to maintain
(aseptic etc)
Manufacturing
labor etc
2016 GP after
selling exp
AP expenses
2017E GP after
sellling exp
GP - Selling expenses 2016-17E Flow
Yili 118%
Mengniu 99%
AP as % of Sales
GP after selling expense as % of Sales
Raw milk cost (Rmbkg-RHS)
伊利股份 (600887SS)
broad positive correlation for Yilis stock price vs milk price
Exhibit 17 China raw milk production still in negative
Monthly raw milk production
Exhibit 18 Import milk powder growth remains subdued
Import milk powder volume yoy
Source Ministry of Agriculture of China
Source China Dairy Industry Association
Exhibit 19 Gap between Global and China milk price now
significantly reduced
China raw milk vs WMP prices
Exhibit 20 Global milk powder price is broadly correlated
Yili stock price vs milk price
Source Bloomberg Datastream
Raw milk production YoY
Import milk powder volume (000 ton)
China raw milk price (RmbKg)
NZ WMP equivalent price (auction only)
NZ WMP equivalent price (auction plus transport VAT)
Yili stock price (RMBsh)
WMP Price (2012 Jan  100 RHS)
伊利股份 (600887SS)
MA a long term growth engine 2020 sales target Rmb100bn
In its 1Q results briefing Yili reiterated its 2020 sales target of Rmb100bn in 2017 This implies a
roughly Rmb20bn gap versus our expectation for organic group sales of Rmb80bn in 2020E
Accordingly we believe inorganic MA will be an important path of growth over the next three
years Yili has taken a prudent approach to MA in the past and recently canceled the proposed
acquisition of Shengmu as both parties mutually agreed not to proceed Going forward we expect
product portfolio and extend the premium positioning
The media (including Bloomberg on May 10 2017) has recently reported Yilis intention to bid for
US organic yogurt brand Stonyfield While we dont take a view of the accuracy of these reports
we believe that Yili could potentially extend its market leadership if it were to introduce a US
brand into China We believe foreign premium brands have potential to be successful in China
given past precedents such as Meiji Danone and Mead Johnson
Sufficient cash Yili had a net cash position of Rmb14bn as of end-2016 and we see it
continuing to increase its cash position over the next few years driven by a stable margin and
limited capex needs
Exhibit 21 We expect Yili to deliver Rmb80bn organic
sales by 2020
Exhibit 22 While Yilis net cash position is sufficient for
potential MA
Source Company data Goldman Sachs Global Investment Research
Source Company data Goldman Sachs Global Investment Research
FY17E FY18E FY19E FY20E
Group sales (rmb mn)
伊利股份 (600887SS)
Best risk-reward among staples 16% OP CAGR 24% ROE 17X PE
Reflecting sales acceleration and better margin outlook we raise our 2018-20E EPS by up to 3%
and with this lift our 12-month target price to Rmb2290 from Rmb2240 Yili is now trading at
18X 12m fwd PE lower than its 10-year historical average of 21X even after
outperforming the market (CSI300) since January 2016 by c26% We continue to value Yili using
2018E EVGCI vs CROCIWACC applying a 10% premium to reflect higher returns and growth
slower growth in the dairy sector Our 12-month target price implies a 2018E PE of 20X below its
historical average of 21X and offers return potential of 21% highest in our sector coverage We
reiterate our Buy rating adding the shares to our Conviction List as our top pick in
the sector
Exhibit 23 Yili is now trading at c18X fwd PE below its
historical average of 21X
Yili PE chart
Exhibit 24 We value Yili based on 2018E CROCIWACC
and EVGCI
TP calculation (priced as of May 24 close)
Source Bloomberg
Source Goldman Sachs Global Investment Research
Exhibit 25 Yili to deliver close to 30% CROCI in 2018E
Source Company data Goldman Sachs Global Investment Research
Hist avg 223x
Fwd 12m PE
avg 207X
PricingReporting Currency
CROCI (2018E)
CROCIWACC (X)
Sector Val-ratio
Valuation premiumdiscount
Adjusted Val-ratio (Y)
Target EVGCI (XY)
GCI (pricing currency mn 2018 E)
Target EV (pricing currency mn 2018E)
Less Net debt  (pricing currency mn)
Less MI (pricing curr mn 2018E)
Implied equity value (Pricing Currency)
Number of shares (mn)
Directors cut TP (Pricing Currency)
Potential upside  (downside)
TP implied 2018E PE
Current 2018E PE
Avg 2017E-
Want Want China Holdings
WH Group Ltd
Biostime International Holdings Limited
Uni-President China Holdings Ltd
Tingyi (Cayman Islands) Holdings
China Modern Dairy Holdings
Tsingtao Brewery (H)
伊利股份 (600887SS)
Exhibit 26 Yili is trading at 17X 2018E PE lower than its Chinese peers average of 18X
Comp sheet for Chineseglobal consumer staples
Note Based on May 24 2017 closing prices Target prices are on a 12-month timeframe NC  Not Covered  denotes stock is on our regional Conviction List
Source Bloomberg Gao Hua Securities Research Goldman Sachs Global Investment Research
Key risks Slower liquid milk sales lower margin from rising cost
We see three key risks to our investment thesis detailed below
growth from weaker-than-expected demand More proactive attempts to gain market share by
peers could also impact sales growth potential
peers and import players could impact Yilis GPM and result in higher AP spending than we
Dilutive MA Yili is currently seeking potential MA opportunities Depending on the price paid
andor performance of any potential acquisition this could impact Yilis high ROE or EPS
EPS 16-18E
EVEBITDA EVEBITDA
Modern Dairy
China FBFMCG
 Excl biological FV chg gain  (loss)
伊利股份 (600887SS)
Exhibit 27 We expect Yili to deliver high-single-digit topline growth and mid-teens OP growth over 2016-2018E
Source Company data Goldman Sachs Global Investment Research
Yili Industrial Group (600887SS)
Divisional PL
16-18E 2yr
16-20E 4yr
Revenues (external only)
Liquid milk (inc Yogurt)
Milk powder and products
Milk powder and products
YoY Growth (%)
Revenues (external only)
Milk powder and products
Milk powder and products
Consolidated PL (Rmb mn)
16-18E 2yr
16-20E 4yr
SGA (excl other revexp)
Selling Exp
Admin Exp
EBIT (reported)
Net Finance Exp
NPAT Attributable to Sholders
WA Shares - Basic
WA Shares - Diluted
EPS - Basic (RmbSh)
EPS - Diluted (RmbSh)
Operating profit (GP less SGA)
Operating profit (GP less SGA)
SGASales
伊利股份 (600887SS)
Gao Hua Securities acknowledges the role of Lincoln Kong CFA and Yuqing Li of Goldman
Sachs in the preparation of this product
伊利股份 (600887SS)
会与本报告中的具体推荐意见或观点直接或间接相关。
投资摘要部分通过将一只股票的主要指标与其行业和市场相比较来评价该股的投资环境。所描述的四个主要指标包括增长、回报、估值倍数和波动性。增长、
回报和估值倍数都是运用数种方法综合计算而成，以确定该股在地区研究行业内所处的百分位排名。
每项指标的准确计算方式可能随着财务年度、行业和所属地区的不同而有所变化，但标准方法如下：
增长是下一年预测与当前年度预测的综合比较，如每股盈利、EBITDA 和收入等。 回报是各项资本回报指标一年预测的加总，如CROCI、平均运用资本回报率
和净资产回报率。 估值倍数根据一年预期估值比率综合计算，如市盈率、股息收益率、EVFCF、EVEBITDA、EVDACF、市净率。 波动性根据12 个月的历史
波动性计算并经股息调整。
Quantum 是提供具体财务报表数据历史、预测和比率的高盛专有数据库，它可以用于对单一公司的深入分析，或在不同行业和市场的公司之间进行比较。
GS SUSTAIN 是侧重于长期做多建议的相对稳定的全球投资策略。GS SUSTAIN 关注名单涵盖了我们认为相对于全球同业具有持续竞争优势和出色的资本回
报、因而有望在长期内表现出色的行业领军企业。我们对领军企业的筛选基于对以下三方面的量化分析：现金投资的现金回报、行业地位和管理水平（公司管
理层对行业面临的环境、社会和企业治理方面管理的有效性）。
廖绪发 CFA：A 股传媒、A 股耐用消费品、A 股食品饮料、中国消费品。
A 股耐用消费品：格力电器、美的集团、青岛海尔。
A 股食品饮料：古井贡酒、洋河股份、贵州茅台、泸州老窖、青青稞酒、山西汾酒、青岛啤酒(A)、五粮液。
A 股传媒：奥飞娱乐、光线传媒、歌华有线、华录百纳、蓝色光标、中南传媒、分众传媒、省广股份、华谊兄弟、IMAX 中国、凤凰传媒、东方明珠、掌趣科
技、万达电影、华策影视。
中国消费品：合生元、光明乳业、现代牧业、华润创业、蒙牛乳业、康师傅控股、青岛啤酒(H)、统一企业、中国旺旺、万洲国际、伊利股份。
没有对下述公司的具体信息披露： 伊利股份 (Rmb1931)
公司评级、研究行业及评级和相关定义
定。任何未获得买入或卖出评级且拥有活跃评级（即不属于暂停评级、暂无评级、暂停研究或没有研究的股票）的股票均被视为中性评级。每个地区投资评估
出评级的分布可能根据地区投资评估委员会的决定而有所不同。此外，每个地区投资评估委员会管理着地区强力买入或卖出名单，该名单以总体潜在回报规模
格。总体潜在回报、目标价格及相关时间范围在每份加入投资名单或重申维持在投资名单的研究报告中都有注明。
的其中一项代表其根据行业历史基本面及或估值对研究对象的投资前景的看法。 具吸引力(A)：未来12 个月内投资前景优于研究范围的历史基本面及或估
值。 中性(N)：未来12 个月内投资前景相对研究范围的历史基本面及或估值持平。 谨慎(C)：未来12 个月内投资前景劣于研究范围的历史基本面及或估
暂无评级(NR)：在高盛于涉及该公司的一项合并交易或战略性交易中担任咨询顾问时并在某些其他情况下，投资评级和目标价格已经根据高盛的政策予以除去。
暂停评级(RS)：由于缺乏足够的基础去确定投资评级或价格目标，或在发表报告方面存在法律、监管或政策的限制，我们已经暂停对这种股票给予投资评级和价
格目标。此前对这种股票作出的投资评级和价格目标(如有的话)将不再有效，因此投资者不应依赖该等资料。 暂停研究(CS)：我们已经暂停对该公司的研究。
没有研究(NC)：我们没有对该公司进行研究。 不存在或不适用(NA)：此资料不存在或不适用。 无意义(NM)：此资料无意义，因此不包括在报告内。
本研究报告仅供我们的客户使用。除了与高盛相关的披露，本研究报告是基于我们认为可靠的目前已公开的信息，但我们不保证该信息的准确性和完整性，客
户也不应该依赖该信息是准确和完整的。报告中的信息、观点、估算和预测均截至报告的发表日，且可能在不事先通知的情况下进行调整。我们会适时地更新
伊利股份 (600887SS)
我们的销售人员、交易员和其它专业人员可能会向我们的客户及自营交易部提供与本研究报告中的观点截然相反的口头或书面市场评论或交易策略。我们的资
产管理部门、自营交易部和投资业务部可能会做出与本报告的建议或表达的意见不一致的投资决策。
本评级，此类评级反映了某只股票相对于报告中描述的研究范围内股票的回报潜力。
在任何要约出售股票或征求购买股票要约的行为为非法的地区，本报告不构成该等出售要约或征求购买要约。本报告不构成个人投资建议，也没有考虑到个别
客户特殊的投资目标、财务状况或需求。客户应考虑本报告中的任何意见或建议是否符合其特定状况，以及(若有必要)寻求专家的意见，包括税务意见。本报告
中提及的投资价格和价值以及这些投资带来的收入可能会波动。过去的表现并不代表未来的表现，未来的回报也无法保证，投资者可能会损失本金。
某些交易，包括牵涉期货、期权和其它衍生工具的交易，有很大的风险，因此并不适合所有投资者。外汇汇率波动有可能对某些投资的价值或价格或来自这一
投资的收入产生不良影响。
策略结构产品，例如，期权差价结构产品，其交易成本可能较高。与交易相关的文件将根据要求提供。
告、模型或其它数据，请联络您的销售代表。